Nazif Alperen Yıldırım

Nazif Alperen Yıldırım

Auto-generated profile, based on publicly available information

Nazif Alperen Yıldırım

Department of Pathology Gulhane Research and Training Hospital Ankara Turkey

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2026 in Annals of Diagnostic Pathology
Verified
Journal Article
Closed access
NYNazif Alperen Yildirim
Nazif Alperen Yildirim
YKYasemin Yuyucu Karabulut
Yasemin Yuyucu Karabulut
DTDuygu Turkbey
Duygu Turkbey
EOEce Ozturk
Ece Ozturk
DKDilara Irem Arslan Kahraman
Dilara Irem Arslan Kahraman
MAMahmut Akgul
Mahmut Akgul

25 November 2025
Verified
Book Chapter
Open access
PDF file
MAMahmut Akgul
Mahmut Akgul
NYNazif Alperen Yıldırım
Nazif Alperen Yıldırım
En sık görülen moleküler olarak tanımlanmış renal kanser olup, çocuk hastalarda da en sık görülen RCC’dir (1). Xp11.2 lokasyonunda bulunan TFE3 geni başta ASPL, SFPQ, PRCC, NONO, RBM10 gibi genlerle translokasyon yapar (2). Klasik morfolojik görünüm bol sitoplazmalı berrak/eozinofilik hücreler, papilla formasyonu ve zaman zaman psammomatöz cisimcik varlığıdır. Ancak TFE3 RCC morfolojisi oldukça heterojendir, bunun nedeni kısmen de olsa TFE3 geninin translokasyon partnerleridir (3). TFE3 FISH testi en önemli testtir ve çoğu vakada tanı için gereklidir, ancak kromozomal inversiyon nedeniyle yanlış negatiflik riski olur. TFE3 IHC teknik olarak çalıştırılması zor bir testtir. Keratinlerde negatiflik ya da azlık, melanositik belirteç pozitifliği, Katepsin K ve GPNMB pozitifliği, uygun morfoloji varlığında TFE3 RCC lehinedir. Hastalığın seyri kısmen translokasyon partnerleriyle ilişkili olsa da genellikle kötüdür.

25 November 2025
Verified
Book Chapter
Open access
PDF file
MAMahmut Akgul
Mahmut Akgul
NYNazif Alperen Yıldırım
Nazif Alperen Yıldırım
TFEB Rearranje RCC: Altıncı kromozomda bulunan TFEB geninin translokasyonu sonucu gelişen nadir böbrek malignitesidir, translokasyon partneri büyük çoğunlukla 11. kromozomdaki MALAT1 genidir.Genç hastalarda daha çok görülür.Bifazik morfolojik özellik gösterir, tümör hücrelerinin çoğunluğu berrak hücre morfolojisindedir, ancak bir kısmı küçük eozinofilik hücreler halinde bazal membran benzeri madde etrafında “rozetlenme” benzeri formasyon yaparlar.Nadir de olsa sadece eozinofilik formları bulunur.TFE3 RCC’ye benzer sekilde pankeratin azlığı, AMACR (rasemaz) pozitifliği görülür. TFEB rearranje tümörlerde hemen her zaman melanositik belirteçler (HMB45, melan A) ve Katepsin K pozitifliği görülür. GPNMB diffüz pozitiftir.TFEB FISH testi altın standarttır.TFE3 RCC’den çok daha nadirdir.Yavaş seyirli (indolan) bir tümördür.TFEB amplifiye RCC: TFEB geni amplifikasyonu sonucu çoğunlukla yaşlı hastalarda meydana gelen nadir ve agresif bir tümördür.Yaşlı erkeklerde görülme sıklığı daha yüksektir.Agresif prezentasyona sahiptir. Renal sinüs ve renal ven invazyonu, renal adipoz doku infiltrasyonu, uzak metastaz sıktır.Eozinofilik yüksek nükleer dereceli tümörler papiller, kribriform, diffüz ve tübüler paternler gösterebilir.TFEB rearranje RCC’den daha az tutarlı olmak üzere melanositik markerlar ve katepsin K gösterir. GPNMB diffüz pozitiftir.TFEB gen amplifikasyonunun 10 kat ve üzeri olması tanı koydurucudur ancak gen amplifikasyon pozitifliğinde eşik değeri tartışmalıdır (örnek: 10 kopyadan az TFEB gen amplifikasyonlu vakalar vardır).

18 September 2026 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
NYNazif Alperen Yildirim
Nazif Alperen Yildirim
EOEce Ozturk
Ece Ozturk
RKRaif Omer Kasap
Raif Omer Kasap
DTDuygu Turkbey
Duygu Turkbey
BBBusra Yaprak Bayrak
Busra Yaprak Bayrak
MAMahmut Akgul
Mahmut Akgul
Background: Working conditions and training quality among pathologists in Türkiye remain insufficiently characterized. This study assessed professional experiences, satisfaction, workload, burnout, academic engagement, and career outlook among pathology residents, specialists, and academic staff practicing in Türkiye. Methods: A cross-sectional, web-based survey was distributed to pathologists in Türkiye. The questionnaire covered demographics, institutional characteristics, motivations for choosing pathology, workload and overtime, satisfaction, burnout indicators, academic activity, and career expectations. Responses were analyzed descriptively and compared across career stages using the Kruskal–Wallis test for continuous or ordinal variables and the Chi-squared or Fisher exact test for categorical variables. Predictors of general job satisfaction were evaluated using multiple linear regression. Results: Overall, 232 pathologists responded; 229 reported career stage, including residents (43.2%), specialists (41.5%), and academic staff (15.3%). Most participants worked in training and research hospitals or public universities. The leading motivations for choosing pathology were limited patient contact, absence of night shifts, and interest in the field. Burnout within the previous 6 months was reported by 76.1% and constant fatigue by 84.7%. General job satisfaction was low across all groups, particularly regarding protected research time, workload, and work–life balance. In regression analysis, overtime and administrative work predicted lower satisfaction, whereas diagnostic and research activities predicted higher satisfaction. Overtime was largely uncompensated and commonly expected by supervisors. Conclusion: Pathology practice in Türkiye is marked by pervasive burnout, chronic fatigue, uncompensated overtime, and low satisfaction, with residents disproportionately affected. Reforms are needed to improve workload distribution, training conditions, work–life balance, and protected research time.

29 June 2026 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
NYNazif Alperen Yıldırım
Nazif Alperen Yıldırım
LFLaila Farid
Laila Farid
DADilara Akbulut
Dilara Akbulut
SMSana Malik
Sana Malik
MSMaryna Slisarenko
Maryna Slisarenko
MAMahmut Akgul
Mahmut Akgul
Background: The 2022 World Health Organization (WHO) fifth Edition introduced major revisions to renal neoplasm classification, incorporating novel and molecularly defined entities. However, the extent to which these advances are adopted in routine pathology practice remains unclear. This international survey evaluated the global diagnostic work-up of kidney tumors, including access to ancillary tests (immunohistochemistry [IHC], fluorescence in situ hybridization [FISH], next-generation sequencing [NGS]) and familiarity with the current classification. Methods: A 30-question online survey was distributed via SurveyMonkey to pathologists involved in renal tumor diagnostics between January and July 2024. The survey assessed demographics, practice setting, training background, WHO classification familiarity, and availability of IHC and molecular testing. Responses were analyzed using descriptive and inferential statistics. Results: Of 427 respondents, 399 (94.8%) reported encountering kidney tumors and were included, representing 45 countries. The most represented were the United States (18.8%), Egypt (15.8%), Turkey (12.6%), the United Kingdom (8.8%), and India (7.3%). Nearly half (49.4%) had >10 years of practice, 41.1% lacked formal genitourinary pathology training, and 70.7% worked in academic settings. IHC was widely available (96.0%), whereas access to FISH (50.1%) and NGS (43.8%) was limited. High-resource academic centers had significantly greater access to molecular diagnostics than community settings (all p < .001). Kidney-specific molecular panels were available in only 18.1% of institutions. Emerging biomarkers (SDHB, FH, cathepsin K, TFE3, TRIM63) were substantially less available than conventional markers. Although 66.3% reported familiarity with the WHO classification, 33.6% cited barriers such as rapid updates, financial constraints, and workload. Conclusions: Marked global disparities persist in renal tumor diagnostics. While IHC is widely accessible, advanced molecular tools and novel biomarkers remain unevenly distributed, underscoring the need for targeted educational and resource-sharing strategies.

25 November 2025
Verified
Book Chapter
Open access
PDF file
MAMahmut Akgul
Mahmut Akgul
NYNazif Alperen Yıldırım
Nazif Alperen Yıldırım
Mitokondriyal enzim olan fumarat hidratazın germline yada sporadik mutasyonu ile seyreden, genellikle agresif gidişli böbrek kanseridir. Germline mutasyonu herediter leiomyomatozis ve renal hücreli karsinom (HLRCC) ile ilişkilidir. Ancak FH RCC sıklıkla sporadik olarak da ortaya çıkar. Genellikle eozinofilik sitolojide tümör hücreleri papiller, kribriform, tübülokistik formasyon gösterirler. En önemli bulgu oldukça belirgin çekirdek ve çekirdek etrafında görülen halodur. Sık bilinen böbrek biomarkerları ile değişken ekspresyon gösterirler, ancak genellikle keratin 7 negatif, rasemaz pozitiftir. Tanı FH IHC kaybı ve 2-süksinil sistein (2SC) sitoplazmik+nükleer boyanması ile konur. Agresif seyreden tümörlerdir. Ancak çok nadir olarak düşük dereceli eozinofilik tümörler şeklinde morfolojiye sahip olabilirler.